- Home
- ABLV vs ACXP Comparison
ABLV vs ACXP Comparison
Compare ABLV & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABLV
- ACXP
- Stock Information
- Founded
- ABLV 2015
- ACXP 2017
- Country
- ABLV China
- ACXP United States
- Employees
- ABLV N/A
- ACXP N/A
- Industry
- ABLV
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- ABLV
- ACXP Health Care
- Exchange
- ABLV Nasdaq
- ACXP Nasdaq
- Market Cap
- ABLV 38.1M
- ACXP 31.4M
- IPO Year
- ABLV N/A
- ACXP 2021
- Fundamental
- Price
- ABLV $1.08
- ACXP $0.88
- Analyst Decision
- ABLV
- ACXP Strong Buy
- Analyst Count
- ABLV 0
- ACXP 1
- Target Price
- ABLV N/A
- ACXP $12.00
- AVG Volume (30 Days)
- ABLV 6.4K
- ACXP 455.1K
- Earning Date
- ABLV 01-01-0001
- ACXP 03-14-2025
- Dividend Yield
- ABLV N/A
- ACXP N/A
- EPS Growth
- ABLV N/A
- ACXP N/A
- EPS
- ABLV N/A
- ACXP N/A
- Revenue
- ABLV $130,087,189.00
- ACXP N/A
- Revenue This Year
- ABLV N/A
- ACXP N/A
- Revenue Next Year
- ABLV N/A
- ACXP N/A
- P/E Ratio
- ABLV N/A
- ACXP N/A
- Revenue Growth
- ABLV N/A
- ACXP N/A
- 52 Week Low
- ABLV $0.55
- ACXP $0.68
- 52 Week High
- ABLV $3.17
- ACXP $4.15
- Technical
- Relative Strength Index (RSI)
- ABLV 63.56
- ACXP 49.25
- Support Level
- ABLV $1.01
- ACXP $0.68
- Resistance Level
- ABLV $1.16
- ACXP $1.25
- Average True Range (ATR)
- ABLV 0.10
- ACXP 0.10
- MACD
- ABLV 0.03
- ACXP 0.02
- Stochastic Oscillator
- ABLV 85.21
- ACXP 35.61
About ABLV Able View Global Inc.
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.